Marc Carlson and Rebecca Colbert.

SAN JUAN CAPISTRANO, Calif.—Allegro Ophthalmics, a biopharmaceutical company focused on the treatment of ocular diseases, has appointed two independent members—Marc Carlson and Rebecca Colbert—to its board of directors, with Colbert serving as chairperson of the audit committee. Both Carlson and Colbert bringing extensive executive level commercial and financial leadership experience from both private and public companies, and will help lead the company’s strategy and direction as it expands its anti-integrin portfolio into new ocular therapeutic areas, according to a statement from Allegro.

Carlson brings more than 35 years of experience commercializing products in a variety of industries and creating value for shareholders. Formerly chief customer officer of DocuSign, Carlson’s expertise helped DocuSign navigate a crowded marketplace and emerge as a leader in its space. His focus on providing measurable value to customers and shareholders alike as well as his ability to develop creative growth stories and global brands were instrumental in the commercial growth of DocuSign from a $50 million private company to a public company with a nearly $10 billion market capitalization over a period of seven years, Allegro said.

Currently chief financial officer at Vertos Medical, Inc., Colbert has more than 15 years of experience working in senior level positions for medical device companies, including in her role as vice president, customer and sales operations, U.S. Surgical at Bausch + Lomb before joining Vertos.

As vice president of finance at eyeonics, Inc., Colbert played a significant role in the company’s filing for its initial public offering and ultimate sale to Bausch + Lomb. She began her career at Deloitte as a certified public accountant.

Allegro’s board also includes ophthalmic innovators Bill Link and Ron Kurtz.